La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Adaptimmune Therapeutics Gestione
Gestione criteri di controllo 3/4
Adaptimmune Therapeutics' Il CEO è Ad Rawcliffe, nominato in Sep2019, e ha un mandato di 4.92 anni. la retribuzione annua totale è $ 2.77M, composta da 23.4% di stipendio e 76.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.1% delle azioni della società, per un valore di $ 287.06K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.7 anni e 9.4 anni.
Informazioni chiave
Ad Rawcliffe
Amministratore delegato
US$2.8m
Compenso totale
| Percentuale dello stipendio del CEO | 23.4% |
| Mandato del CEO | 4.9yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 4.7yrs |
| Durata media del Consiglio di amministrazione | 9.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$3m | US$650k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
| Sep 30 2018 | n/a | n/a | -US$87m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$69m |
| Dec 31 2017 | US$2m | US$444k | -US$70m |
Compensazione vs Mercato: La retribuzione totale di Ad ($USD 2.77M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.55M ).
Compensazione vs guadagni: La retribuzione di Ad è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Ad Rawcliffe (52 yo)
4.9yrs
Mandato
US$2,774,041
Compensazione
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.9yrs | US$2.77m | 0.10% $ 297.7k | |
| Co-Founder & Chief Business & Strategy Officer | no data | US$1.18m | 0.12% $ 336.1k | |
| Chief Financial Officer | 4.3yrs | US$1.17m | 0.0063% $ 17.9k | |
| Chief Operating Officer | 7.4yrs | US$1.22m | 0.064% $ 183.9k | |
| Chief Medical Officer | 4.6yrs | US$1.18m | 0.037% $ 106.0k | |
| Chief Scientific Officer | 2.3yrs | Nessun dato | 0.0049% $ 13.9k | |
| VP of Corporate Affairs & Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP & General Council | 8.8yrs | Nessun dato | Nessun dato | |
| Senior Director of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Patient Supply Officer | 5yrs | US$1.72m | 0.053% $ 152.5k | |
| Senior Vice President of Late Stage Development | 4.7yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | US$2.19m | 0.015% $ 42.9k |
4.7yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di ADAP è considerato esperto (durata media dell'incarico 4.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.9yrs | US$2.77m | 0.10% $ 297.7k | |
| Independent Chairman of the Board of Directors | 9.5yrs | US$174.83k | 0% $ 0 | |
| Independent Non-Executive Director | 9.5yrs | US$111.54k | 0% $ 0 | |
| Independent Non-Executive Director | 9.4yrs | US$128.80k | 0.0093% $ 26.8k | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 6.1yrs | US$117.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato |
9.4yrs
Durata media
59.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ADAP sono considerati esperti (durata media dell'incarico 9.4 anni).